Financial Performance - The net profit attributable to shareholders for 2023 was 580 million yuan, a decrease of 64.84% year-on-year, primarily due to a significant decline in demand for infection protection products, resulting in a revenue drop of approximately 3.82 billion yuan[12]. - The company's operating revenue for 2023 was ¥8,185,022,057.20, a decrease of 27.89% compared to the previous year[24]. - Net profit attributable to shareholders for 2023 was ¥580,403,232.37, down 64.84% year-over-year[24]. - The net profit after deducting non-recurring gains and losses was ¥412,027,497.25, reflecting a 73.61% decline from the previous year[24]. - The net cash flow from operating activities decreased by 64.36% to ¥1,063,326,232.23[25]. - Basic earnings per share for 2023 were ¥0.98, a drop of 64.87% compared to ¥3.90 in 2022[24]. - Total assets as of the end of 2023 were ¥17,112,022,449.97, representing a 6.25% decrease from the previous year[24]. - Net assets attributable to shareholders decreased by 1.59% to ¥11,533,224,328.00[24]. - The decline in net profit was primarily due to a significant drop in demand for infection protection products, resulting in a revenue decrease of approximately ¥3.82 billion[24]. - Goodwill impairment also contributed to a reduction in net profit by approximately ¥188 million[24]. Revenue Breakdown - The company's total revenue for Q1 was approximately CNY 2.35 billion, while Q4 revenue was around CNY 2.17 billion, showing a decline in Q3 revenue to CNY 1.74 billion[26]. - The net profit attributable to shareholders for Q3 was CNY 1.47 billion, but it turned negative in Q4 with a loss of approximately CNY 1.57 billion, primarily due to the reversal of gains from urban renewal projects[26]. - The medical consumables business generated a total revenue of 3.86 billion yuan in 2023, a year-on-year decrease of 46.7% due to a significant decline in market demand for infection protection products[90]. - The conventional medical consumables segment achieved a revenue of 2.95 billion yuan, reflecting a year-on-year growth of 17.3%, laying a solid foundation for long-term development[90]. - The revenue from infection protection products decreased by 3.82 billion yuan, a decline of 80.7% year-on-year, while traditional dressing products generated 1.15 billion yuan, up 7.0%[91]. - The overseas channel revenue reached 1.45 billion yuan, achieving a growth of 15.4% and accounting for 37.5% of the medical segment's total revenue[92]. - The consumer goods segment achieved a revenue of 4.26 billion yuan, with a year-on-year increase of 6.4%[93]. Market Trends and Opportunities - The low-value medical consumables market in China is projected to reach CNY 221.3 billion by 2025, indicating substantial growth potential for the company's medical business[38]. - The aging population in China is expected to reach 296 million by the end of 2023, accounting for 21.1% of the total population, which will further drive demand for medical devices[33]. - The domestic market for surgical infection control products is expected to reach $3.688 billion by 2026, with a CAGR of 4.9%[39]. - The global market for customized surgical kits is projected to grow to $21.347 billion by 2026, with a CAGR of 10.2%, while China's market is expected to reach $1.504 billion, growing at a CAGR of 12.2%[39]. - The global advanced wound dressing market was valued at $5.846 billion in 2020 and is anticipated to reach $7.230 billion by 2027[40]. - The Chinese market for advanced wound dressings is rapidly growing, driven by factors such as an aging population and increased awareness of high-end wound care products[40]. Product Development and Innovation - The company aims to leverage advanced technologies such as AI and the metaverse to improve operational efficiency and management quality[7]. - The company has developed a cooling gauze product that exceeds national standards by 30% in instant cooling value and has improved the softness of cotton towels by 15%[97]. - The company has successfully launched biodegradable masks and high-transparency N95 medical protective masks, enhancing the environmental attributes and comfort of mask products[78]. - The company launched several new products, including a biodegradable agricultural cultivation fabric and a super-soft, thick cotton non-woven fabric, enhancing product competitiveness[136][137]. - The investment in R&D for the development of a collagen dressing product is currently in the mass production stage, aiming to enter the high-end dressing product line[137]. Strategic Initiatives - The company has actively adjusted its product structure and sought opportunities in international markets to mitigate the impact of domestic market adjustments[3]. - The company plans to enhance its service response capabilities for overseas major clients and accelerate the entry speed into domestic hospitals[6]. - The company aims to expand its market presence through strategic partnerships and product innovation, aligning with consumer trends towards health and sustainability[71]. - The company is focusing on smart manufacturing and logistics to achieve automation and digitalization in production processes[87]. - The company has established partnerships with universities to advance research in advanced fiber materials and low-carbon production processes, aiming for sustainable development[97]. Corporate Governance and Social Responsibility - The company has maintained a high standard of corporate governance, receiving awards such as "Best Practice of the Board Office" and "5A Evaluation of the Secretary of the Board" for two consecutive years[179]. - The company has voluntarily disclosed its Corporate Social Responsibility Report for three consecutive years, showcasing its commitment to social responsibility and sustainable development[179]. - The company actively respects and maintains the legitimate rights and interests of stakeholders, balancing the interests of shareholders, employees, and society[190]. - The company has received an "A" rating for information disclosure from the Shenzhen Stock Exchange for both 2021 and 2022, highlighting its commitment to transparency[180]. Challenges and Risks - The company recognizes the risks associated with changes in industry policies and standards, which could significantly impact its operations if not adapted to promptly[168]. - The company's main raw materials are cotton and cotton-derived products, with cotton price fluctuations posing a significant cost pressure risk; if raw material prices rise continuously, it may negatively impact profitability[169]. - In 2023, the company's export sales accounted for 18.86% of total revenue, with exchange rate fluctuations affecting both export pricing and procurement costs[170].

中国国际金融股份有限公司 关于稳健医疗用品股份有限公司 2023 年度证券与衍生品投资情况的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为稳健 医疗用品股份有限公司（以下简称"稳健医疗"或"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法（2023 年修订）》 《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务（2022 年修订）》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 （2023 年 12 月修订）》等相关法律、法规和规范性文件的规定，对稳健医疗 2023 年度证券与衍生品投资情况进行了核查，具体核查情况如下： 一、证券与衍生品投资的审批情况 2023 年 8 月 15 日，公司召开第三届董事会第十六次会议、第三届监事会第 十一次会议审议通过了《关于公司开展外汇套期保值业务的议案》，拟以累计不 超过 10.00 亿元人民币（或等值外币）开展以套期保值为目的的远期、期权等汇 率衍生品投资，在上述额度范围内，资金可循环使用，授权期限自公司董事会审 议通过之日起 12 个月内有效。 二、2023 年度 ...

根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作(2023 年修订)》的规定，独立董事应 当每年对独立性情况进行自查，并将自查情况提交董事会。董事会应当每年对 在任独立董事独立性情况进行评估并出具专项意见，与年度报告同时披露。基 于此，稳健医疗用品股份有限公司（以下简称"公司"）董事会，就公司在任 独立董事彭剑锋、Key Ke Liu、谢家伟的独立性情况进行评估并出具如下专项 意见： 根据公司独立董事自查及其在公司的履职情况，董事会认为公司独立董事 均能够胜任独立董事的职责要求，其未在公司担任除独立董事以外的任何职 务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 妨碍我们进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合 《上市公司独立董事管理办法》等法律法规及《公司章程》中关于独立董事的 任职资格及独立性的相关要求。 稳健医疗用品股份有限公司董事会 稳健医疗用品股份有限公司 董事会关于独立董事独立性自查情况的专项报告 二〇二四年四月二十五日 ...

证券代码：300888 证券简称：稳健医疗 公告编号：2024-019 稳健医疗用品股份有限公司 第三届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 稳健医疗用品股份有限公司（以下简称"公司"）第三届监事会第十五次会 议于 2024 年 4 月 23 日以现场方式召开，会议通知已于 2024 年 4 月 14 日通过 邮件和即时通信工具的方式送达各位监事。本次会议应出席监事 3 人，实际出席 监事 3 人。本次会议由监事会主席张婷婷女士召集并主持，董事会秘书列席会 议。会议的出席人数、召集、召开程序和审议内容均符合《公司法》等有关法律、 法规、规范性文件及《公司章程》的有关规定，会议合法有效。 二、监事会会议审议情况 1.审议通过《关于〈2023 年度监事会工作报告〉的议案》。 根据公司监事会 2023 年工作情况，公司监事会组织编写了《2023 年度监事 会工作报告》，对 2023 年度监事会工作的主要方面进行了回顾、总结。具体内 容详见公司同日披露在巨潮资讯网（www.cninfo.com.cn）的《2 ...

一、 本次激励计划已履行的相关审批程序 （一）2020 年 11 月 27 日，公司第二届董事会第十五次会议审议通过了 《关于公司<2020 年限制性股票激励计划（草案）>及其摘要的议案》、《关于公 司<2020 年限制性股票激励计划实施考核管理办法>的议案》、《关于提请公司股 东大会授权董事会办理股权激励相关事宜的议案》、《关于提请召开公司 2020 年 第六次临时股东大会的议案》。 同日，公司第二届监事会第九次会议审议通过了《关于公司<2020 年限制 性股票激励计划（草案）>及其摘要的议案》、《关于公司<2020 年限制性股票激 励计划实施考核管理办法>的议案》、《关于核实公司<2020 年限制性股票激励计 划激励对象名单>的议案》。 证券代码：300888 证券简称：稳健医疗 公告编号：2024-024 稳健医疗用品股份有限公司 关于作废部分已授予尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 稳健医疗用品股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开 第三届董事会第二十次会议和第三届监事会第十五次会 ...

中国国际金融股份有限公司 关于稳健医疗用品股份有限公司 使用闲置自有资金购买理财产品的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为稳 健医疗用品股份有限公司（以下简称"稳健医疗"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则（2023 年 8 月修订）》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作（2023 年 12 月修订）》等规则 的要求，对稳健医疗使用闲置自有资金购买理财产品的事项进行了审慎核查，核 查情况及核查意见如下： 一、使用闲置自有资金购买理财产品的情况 1、资金来源 公司及子公司暂时闲置的自有资金。 2、投资目的 在保证日常经营资金需求和资金安全的前提下，为更好地实现公司资产的保 值与增值，提高公司闲置自有资金利用率，节省财务费用，增加公司收益，保障 公司股东利益，公司及子公司拟使用暂时闲置的自有资金进行理财产品购买。 3、投资种类 投资品种为安全性高、流动性好的产品，包括但不限于银行理财产品、银行 结构性存款产品、信托产品等产品及其他根据公司内部决策 ...

证券代码：300888 证券简称：稳健医疗 公告编号：2024-026 稳健医疗用品股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2023 年年度股东大会 （二）会议召集人：公司董事会 （三）本次股东大会的召集、召开符合有关法律、行政法规、部门规章、规 范性文件和公司章程的相关规定。 公司股东应选择现场投票、网络投票中的一种表决方式。同一表决权出现重 复投票的以第一次有效投票结果为准。 （六）会议的股权登记日：2024 年 5 月 14 日（星期二） （七）会议出席对象： 1.截至 2024 年 5 月 14 日（股权登记日）下午交易收市后，在中国证券登记 结算有限责任公司深圳分公司登记在册的公司全体股东均有权出席股东大会。不 能亲自出席股东大会现场会议的股东可以书面委托代理人出席会议并参与表决 （该股东代理人不必是公司股东，授权委托书格式详见附件二），或在网络投票 时间内参加网络投票； （四）会议召开时间： 1.现场会议召开时间：2024 年 5 月 21 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥1,909,017,281.07, a decrease of 18.84% compared to ¥2,352,114,690.56 in the same period last year[4]. - Net profit attributable to shareholders decreased by 51.60% to ¥182,424,811.95 from ¥376,938,135.34 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥144,201,815.60, down 53.46% from ¥309,834,876.09 in the previous year[4]. - Basic and diluted earnings per share both decreased by 51.56% to ¥0.31 from ¥0.64 year-on-year[4]. - In Q1 2024, the company reported a total revenue of 1.91 billion yuan, a year-on-year decrease of 18.8%[21]. - Net profit attributable to shareholders was 180 million yuan, down 51.6% year-on-year[21]. - Net profit for Q1 2024 was CNY 193,513,122.53, representing a decline of 50.1% from CNY 387,940,532.93 in Q1 2023[33]. - The company reported a total comprehensive income of CNY 194,542,000.87, down from CNY 387,215,004.85 in Q1 2023[34]. Cash Flow and Investments - The company's cash flow from operating activities improved by 26.78%, with a net cash outflow of ¥163,462,761.04 compared to ¥223,247,317.38 in the same period last year[4]. - The net cash flow from investment activities was -309,795,884.33, compared to -178,675,407.47 in the previous year, indicating a decline in investment performance[38]. - Cash inflow from financing activities totaled 453,003,451.87, down from 683,000,000.00 year-over-year[38]. - The net cash flow from financing activities was -484,059,598.07, contrasting with a positive net flow of 262,960,743.92 in the same quarter last year[38]. - The company reported a total cash outflow from investment activities of 1,124,307,276.17, compared to 1,624,404,139.25 in the prior year[38]. - The cash outflow for repayment of debts was 733,000,000.00, significantly higher than 363,000,000.00 in the previous year[38]. - The company’s cash and cash equivalents decreased by 954,811,754.85 during the quarter, compared to a decrease of 142,627,979.28 in the same quarter last year[38]. - The company's cash and cash equivalents at the end of the period were approximately 3.75 billion yuan, down from 4.71 billion yuan at the beginning of the period[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥16,494,937,257.25, a decrease of 3.61% from ¥17,112,022,449.97 at the end of the previous year[4]. - Total liabilities decreased to approximately 4.33 billion yuan from 5.00 billion yuan[29]. - The total liabilities and equity amounted to CNY 16,494,937,257.25, a decrease from CNY 17,112,022,449.97 year-over-year[30]. - The total equity attributable to shareholders of the parent company increased slightly to CNY 11,572,720,973.48 from CNY 11,533,224,328.00[30]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,872[17]. - The largest shareholder, Steady Group Limited, holds 69.12% of the shares, totaling 406,614,387 shares[17]. - The company has a total of 4,354,560 shares held in the repurchase special account as of March 31, 2024[18]. - The number of shares with limited sales at the end of the period is 406,766,052, with 10,500 shares released from restrictions during the period[20]. - The company has no preferred shareholders or major changes in the top 10 shareholders participating in margin trading[19]. - The top 10 shareholders hold a combined total of 99.99% of the shares, with no significant changes in their holdings[19]. - The company has not issued any new shares or products during this reporting period[20]. - The company plans to maintain its current shareholder structure without any immediate changes in strategy or market expansion[20]. Research and Development - R&D expenses decreased by 31.64% to ¥75,999,859.76 from ¥111,178,989.49 in the previous year, primarily due to a reduction in R&D projects[13]. - Research and development expenses decreased to CNY 75,999,859.76, down 31.7% from CNY 111,178,989.49 in the previous year[33]. Taxation - The company received tax refunds of ¥25,352,683.07, an increase of 130.29% compared to ¥11,008,837.69 in the same period last year[15]. - Cash paid for various taxes decreased by 65.54% to ¥100,041,606.75 from ¥290,271,355.72, reflecting a decline in medical performance[15]. Product Performance - Medical consumables revenue was 860 million yuan, a decline of 37.3% year-on-year, while infection protection products saw a significant drop of 87.6% to 80 million yuan[23]. - Regular medical consumables revenue grew by 4.3% to 780 million yuan, with high-end wound dressing products increasing by 33.9% to 180 million yuan[23]. - International sales channels for medical consumables achieved 380 million yuan, up 21.3% year-on-year, accounting for 44.6% of the medical consumables revenue[23]. - Health consumer products revenue reached 1.04 billion yuan, a growth of 7.1% year-on-year, with non-woven consumer products growing by 10.0% to 550 million yuan[23]. - The core product, wet and dry cotton towels, generated 270 million yuan in revenue, reflecting a 20.0% increase[23]. Other Information - The company has not reported any mergers or acquisitions in this quarter[20]. - There are no new technological developments or product launches mentioned in the report[20]. - The company has not yet adopted the new accounting standards for the current year[39]. - The first quarter report was not audited[40]. - The board of directors issued the report on April 25, 2024[41].

稳健医疗用品股份有限公司 2023 年度独立董事述职报告 （彭剑锋） 各位股东及股东代表： 作为稳健医疗用品股份有限公司（以下简称"公司"）董事会的独立董事， 在任职期间，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 市公司治理准则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市 公司规范运作》《公司章程》及《公司独立董事工作制度》等法律法规、规范性 文件的相关规定和要求，积极出席相关会议，忠实、勤勉地履行了独立董事的职 责，维护了公司和股东特别是中小股东的切身利益。现将本人2023年度的履职情 况汇报如下： 一、独立董事基本情况 本人彭剑锋，1961年出生，中国国籍，无境外永久居留权，中国人民大学硕 士学位。1986年至今，在中国人民大学劳动人事学院陆续担任讲师、副教授和教 授；此前，陆续担任天音通信控股股份有限公司、山河智能装备股份有限公司、 歌尔股份有限公司、中文天地出版传媒集团股份有限公司、海尔智家股份有限公 司、招商蛇口工业区控股股份有限公司和周大生珠宝股份有限公司独立董事；现 任海能达通信股份有限公司非独立董事、建信信托有限责任公司董事、光启技术 股份有限公司独立董事以及 ...

稳健医疗用品股份有限公司 2023 年度独立董事述职报告 （Key Ke Liu） 各位股东及股东代表： 作为稳健医疗用品股份有限公司（以下简称"公司"）董事会的独立董事， 在任职期间，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 市公司治理准则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市 公司规范运作》《公司章程》及《公司独立董事工作制度》等法律法规、规范性 文件的相关规定和要求，积极出席相关会议，忠实、勤勉地履行了独立董事的职 责，维护了公司和股东特别是中小股东的切身利益。现将本人2023年度的履职情 况汇报如下： 一、独立董事基本情况 本人Key Ke Liu，中文名"刘科"，1964年出生，美国国籍，西北大学化学 工程学士学位和硕士学位，美国纽约市立大学博士学位，美国伦斯勒理工学院管 理学硕士，澳大利亚国家工程院外籍院士。曾任美国通用电气全球研发中心(GE Global Research)首席科学家、加州理工学院电力环境与能源研究中心（PEER） 董事、国际匹兹堡煤炭大会（PCC）会议组织董事、国际匹茨堡煤炭会议组织理 事、宁波江丰电子材料股份有限公司、深圳市惠程信息科技 ...